Biopharma Asks for Emergent Use in US of New COVID Drug
Source: Edward White  (9/29/22)
The requested approval is specifically for critically ill patients, a population for which the U.S. Food and Drug Administration granted the therapeutic fast track status, noted an H.C. Wainwright & Co. report. More >

Oncology Co.'s Shares Erupt on Signing Global License Deal
Source: Streetwise Reports  (9/27/22)
Shares of clinical-stage immuno-oncology company LAVA Therapeutics NV traded nearly 100% higher yesterday after the firm reported that it has entered into a global licensing agreement with Seagen Inc. to advance its LAVA-1223, a preclinical gamma delta bispecific T cell engager designed for use in the treatment of EGFR-expressing solid tumors. More >

Opportunity for Investors Found in Psychedelics Space
Source: Patrick R. Trucchio  (9/27/22)
Treatment of alcohol use disorder with psychedelics plus therapy is effective, according to existing data, and the potential global market is large, noted an H.C. Wainwright & Co. report. More >

US Biotech Firm Keeps Growing Revenue
Source: Scott Henry  (9/26/22)
Revenue last quarter was strong, and management expects to increase revenue 20% this fiscal year, noted a ROTH Capital Partners report. More >

Co.'s Clinical Program in HPV+ Cancers Gives It a Buy Rating
Source: Dr. Joseph Pantginis  (9/23/22)
To fund continued development of its lead immunotherapy candidate, the U.S.-based biopharma recently completed a $35 million debt financing agreement, noted an H.C. Wainwright & Co. report. More >

Analyst Says Buy Before Biotech Co.'s Clinical Trials
Source: Dr. David Nierengarten  (9/23/22)
Argenx SE has "several upcoming catalysts," noted a Wedbush report. More >

Telemedicine Co. Says It's Set To Thrive in Post-Pandemic World
Source: Streetwise Reports  (9/21/22)
The pandemic changed the way many people get their basic healthcare, giving a big opening to telemedicine companies like Reliq Health Technologies Inc. More >

FDA Approves Hearing Loss Drug for Child Chemo Patients
Source: Streetwise Reports  (9/21/22)
Shares of Fennec Pharmaceuticals Inc. traded 14% higher after the company reported it received approval from the U.S. FDA for its PEDMARK® (sodium thiosulfate injection) for use in reducing the risk of ototoxicity in pediatric patients who are undergoing or completed chemotherapy for non-metastatic solid tumors. More >

Dermatology Co.'s Target Price Much Higher Than Current
Source: Dr. Jonathan Aschoff  (9/20/22)
The biopharma's strategic marketing campaign "should continue growing U.S. sales to current and new customers," noted a ROTH Capital Partners report. More >

Important Catalyst Expected Soon for Cancer Drug Co.
Source: Dr. David Nierengarten  (9/20/22)
The biopharma should announce initial clinical trial data on its lead small molecule candidate by year-end, noted a Wedbush report. More >

Biopharma Co.'s Shares Rise on Phase 3 Migraine Trial Data
Source: Streetwise Reports  (9/20/22)
Satsuma Pharmaceuticals Inc. shares traded 12% higher to a new 52-week high after the company reported positive results from its Phase 3 long-term study of STS101 for use in acute treatment of migraine attacks. The company expects to receive further efficacy data from its Phase 3 SUMMIT trial in Q4/22, which it believes will support submission of an NDA with the U.S. FDA in Q1/23. More >

Second Trial of New Eczema Drug To Commence in Q4/22
Source: Dr. Yi Chen  (9/17/22)
The purpose behind this complementary study is to potentially expand the treatment's target patient population, noted an H.C. Wainwright & Co. report. More >

FDA Grants Approval for Drug Improving Kidney Function
Source: Streetwise Reports  (9/16/22)
Shares of Mallinckrodt Plc. traded 28% higher yesterday after the company reported that the U.S. FDA has issued approval for its Terlivaz® (terlipressin) for injection for use in treating hepatorenal syndrome, a serious and life-threatening condition that is accompanied by rapid reduction in kidney function. More >

Price Target on US Biopharma Co. Boosted by $15
Source: Julian Harrison  (9/15/22)
The increase came after positive clinical trial results on one of its lead drug candidates differentiating it from a competitor, noted a BTIG report. More >

New Drug Shown To Help Patients With Desmoid Tumors
Source: Dr. David Nierengarten  (9/15/22)
This oral gamma-secretase inhibitor met the primary and secondary endpoints in a Phase 3 clinical trial, noted a Wedbush report. More >

NDA for Dry Eye Disease Drug on Track for Q4/22 Submission
Source: Justin Kim   (9/15/22)
This and the biopharma's other treatment candidates for ocular diseases are underappreciated, which translates to an investment opportunity, noted an Oppenheimer report. More >

Several Trials of Co.'s Fluid Pump To Read Out This Year
Source: Dr. Yi Chen  (9/14/22)
Positive topline data could boost the share price of this Swiss medical device firm, noted an H.C. Wainwright & Co. report. More >

Co. Advancing Drug Class With Broad Potential
Source: Dr. Thomas Shrader   (9/13/22)
This developer of C1q-targeting therapeutics, with a catalyst-rich 18 months ahead, warrants analyst coverage, noted a BTIG report. More >

Biotech Co.'s Target Six Times Current Price
Source: Francois Brisebois  (9/13/22)
One Phase 2 clinical trial showing LSD reduced symptoms of anxiety bodes well for other studies of LSD in this indication. In light of this, Oppenheimer & Co. gave this biotech company a target price that is over six times its current share price. More >

Expert Says Life Science Co.'s Technical Setup Is 'Exceptionally Positive and Keeps Getting Better'
Source: Clive Maund  (9/13/22)
Expert Clive Maund reviews the 6-month and 15-month charts for Awakn Life Sciences Corp. to explain why he thinks this company's technical setup is exceptionally positive. More >

Healthcare Co.'s To Develop Fast-Dissolving MDMA Tablet
Source: Streetwise Reports  (9/12/22)
One biopharma co. is teaming with a much larger pharmaceutical company to develop a fast-dissolving oral tablet to deliver MDMA to patients with Alcohol Use Disorder. Find out why developing an oral tablet could benefit the company in the long run. More >

Analyst Says Biopharma's New Inhaled Antifungal Drug Shows Promise
Source: Dr. Jonathan Aschoff  (9/12/22)
Trial results are expected later this month, but anecdotal data available now suggest the findings should be positive, noted a ROTH Capital Partners report. More >

US Co. To Regain All Rights to Its AGHD Diagnostic Test
Source: Dr. Ram Selvaraju  (9/8/22)
This is set to happen because the biopharma's commercialization partner recently terminated its agreement over the product, noted an H.C. Wainwright & Co. report. More >

Medtech Co. Meets Primary Endpoints in Ph. 3 Glaucoma Trials
Source: Streetwise Reports  (9/8/22)
Glaukos Corp.'s shares traded 18% higher yesterday after the company reported that in two separate Phase 3 trials, its iDose TR met its primary efficacy endpoints by lowering intraocular pressure in glaucoma patients. More >

Biopharma Co. Receives Approval From FDA Panel for ALS Drug
Source: Streetwise Reports  (9/8/22)
Amylyx Pharmaceuticals Inc.'s shares traded 51% higher after the company reported that a U.S. FDA advisory committee has voted to support approval of the firm's AMX0035 for use in treating amyotrophic lateral sclerosis. Although the committee's recommendation is not binding, it is expected that the decision will provide staunch support for approval of the firm's pending NDA for AMX0035, which has a target action date of September 29, 2022. More >